ABSTRACT. The effect of exocrine pancreatic function on AUC, area under the curve the pharmacokinetics of the choramphenicol oral capsule C1, clearance (CAP-base), chloramphenicol palmitate oral liquid (CAPVdarea, volume of distribution P), and chloramphenicol succinate intravenous (CAP-S) MIC, minimum inhibitory concentration formulations was evaluated in 10 patients, aged 16-30 yr, with cystic fibrosis. Pancreatic insufficiency was assessed in each patient by measuring the absorption of p-aminobenzoic acid after oral administration of N-benzoyl-L-tyrosyl-p-aminobenzoic acid which requires chymotrypsin to cleave p-aminobenzoic from the parent molecule. In a controlled cross-over design, the overall biodisposition of each formulation was assessed in each patient with or without concurrent administration of oral pancreatic enzymes. The relative amounts of active chloramphenicol available in systemic circulation was CAP-base > CAP-S > CAP-P. Pancreatic enzyme replacement had little effect on the biodisposition parameters for the CAP-base and CAP-S formulation, but significantly increased the peak concentration and bioavailability of the CAP-P formulation. Although pancreatic enzyme replacement improved the absorption characteristics of the CAP-P formulation, absorption remained prolonged and unreliable. Serum concentration-time profiles for either CAP-base or CAP-S consistently exceeded the MIC of important nonpseudomonal pathogens. This finding was not observed after CAP-P administration independent of pancreatic enzyme replacement. The results of this study support the continued clinical use of either CAP-base or CAP-S, but the cautious use of CAP-P formulations in CF patients with concurrent pancreatic insufficiency. (Pediatr Res 23: 388-392, 1988) Abbreviations CAP, chloramphenicol CAP is an effective antimicrobial agent widely used in pediatric practice (I). Currently, three systemically available pharmaceutical formulations are available for use in clinical practice: CAP-S for iv administration, CAP-P as an oral suspension, and CAPbase as an oral capsule. Both prodrug formulations (CAP-S and CAP-P) are devoid of antibacterial activity and require hydrolysis in vivo to liberate antimicrobially active CAP. CAP-S appears to be hydrolyzed primarily by hepatic esterases, whereas CAP-P appears to be hydrolyzed within the gastrointestinal tract by pancreatic lipase (1) (2) (3) . Recent data in young infants and some children have demonstrated erratic hydrolysis of CAP-S, whereas the effects of exocrine pancreatic insufficiency on the hydrolysis of CAP-P remain ill defined ( 1 , 4, 5).
CAP is commonly used for oral antimicrobial therapy of ambulatory patients with CF. Despite the widespread use of the drug, only limited data are available describing its biodisposition in CF patients. This lack of pharmacologic data appears to result primarily from dificulties inherent in describing the pharmacokinetics of prodrugs. The present investigation had a dual purpose: l ) to describe the overall biodisposition of the three available CAP formulations in patients with CF, and 2) to determine the effects of PER therapy on CAP biodisposition in patients with CF.
MATERIALS AND METHODS

CAP&, CAP-succinate CAP-P, CAP-palmitate
Subjects. Hospitalized CF patients r 12 yr old requiring PER CAP-base, CAP-free base who had previously received CAP therapy were eligible for enrollment into this study. Patients were excluded from enrolliv, intravenous ment if they had a history of CAP hypersensitivity, leukopenia PER, pancreatic enzyme replacement CF, cystic fibrosis (white blood cells <4000 cells/mm3), thrombocytopenia (platelet N-PABA, N-benzoyl-L-tyrosyl-p-aminobenzoic acid count ~100,000/mm3), anemia (hematocrit <35%), significant Patients were allowed lunch with their usual PER a minimum of 3.5 h after CAP administration. Each pharmacokinetic evaluation was separated by at least 36 h. CAP-S was administered iv through a peripheral vein over -4 min; CAP-P and CAP-base were administered orally along with -240 ml water. All three CAP formulations used were obtained from a single manufacturer (ParkeDavis Laboratories, Detroit, MI). Venous blood samples (minimum 3 ml) for the determination of CAP were obtained at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 7, and 12 h after iv CAP-S administration and at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 h after oral CAP-P and CAP-base administration. Blood was collected in sterile glass tubes, allowed to clot, and immediately centrifuged. Serum was removed and stored at -70" C until analyzed. All samples were analyzed within 14 days of collection.
Assessment of exocrine pancreatic function. Exocrine pancreatic insufficiency was confirmed in each study patient by the use of N-PABA (7, 8) . Patients discontinued their usual PER therapy for 24 h and were evaluated after an overnight fast. N-PABA, 500 mg in 240 ml orange juice, was administered orally with a large breakfast without PER. Patients were asked to void before N-PABA administration and all urine excreted over the next 6 h was collected. Urinary PABA was quantitated by HPLC and confirmed calorimetrically by a modification (9) of the procedure originally reported by Bratten and Marshall (10) . Urinary PABA excretion 555% of the administered N-PABA dose indicated exocrine pancreatic insufficiency (8, 1 1).
Cleavage of palmitate ester. An in vitro experiment using Pancrease (McNeil Pharmaceuticals, Springhouse, PA) was undertaken to confirm that PER was capable of cleaving the palmitate ester of CAP. CAP-palmitate oral liquid, 200 mg, was added to each of three beakers containing 200 ml0.45% sodium chloride and 8 mEq KC1. Beakers were kept in a water bath maintained at 37" C. The first beaker served as a control and had no Pancrease capsules added. To the second and third beaker, 2 and 4 whole Pancrease capsules were added, respectively. The pH of the three solutions was decreased to 2.1 with 12 M HC1. After 1 h the solutions were alkalinized to pH 6.5
with NaHC03. The solutions were stirred every 15 min. Aliquots (100 p1) were withdrawn from each beaker at times 0, 1 (just before alkalinization), 2, 3, and 4 h. These were diluted with 900 ~1 0.9% sodium chloride and assayed immediately for CAP by HPLC as described below. A titrimetric method was used to determine lipase activity at the 4-h sampling (12) . Determination of CAP by HPLC. To prepare serum samples for chromatography, 0.18 ml acetonitrile and 0.02 ml water were added to 0.2 ml serum. The mixture was warmed by hand, vortexed for 10 s, and centrifuged for 2 min. The supernatant was transferred into a 12 x 75 mm glass tube which was capped with a polyethylene snap cap and stored in ice until 10 min before injection. Chloramphenicol concentrations in serum were determined by HPLC using a Varian model 5020 ternary liquid chromatograph. Briefly, samples were injected into a Valco automated valve fitted with a 25 loop and pumped at 1.2 mI/min through a 30 cm X 4 mm Micropack MCH 10 reverse phase column. The column was temperature controlled at 30" C with a column heater and was preceded by a 4 cm x 4 mrn guard column filled with Vydac 40 Pm pellicular reverse phase packing. Peaks were detected at 276 nm with a Varian, model UV 100 variable wavelength detector, and printed on a Linear model 29 1 printer. Peak areas were quantitated on a CDS 11 IL integrator recorder. The mobile phase consisted of acetonitrile: 0.2% phosphoric acid, 27:73 (v/v). The limit of CAP detectability was 0.2 mg/ liter. The between day coefficient of variation was 2.8% at 25 mglliter.
Pharmacokinetic analysis. The biodisposition of CAP after administration of the three different formulations in the presence or absence of PER was characterized for each patient using noncompartmental and graphical techniques (1 3). Serum CAP concentrations were plotted against time on a semilogarithmic scale. The elimination rate constant, P, was determined from the slope of the terminal portion of the serum concentration time curve; elimination th as 0.693/@. The area under the serum concentration time curve (AUC) was obtained by using the linear trapezoidal rule up to the final measured serum concentration and extrapolated to infinity. Due to difficulties inherent in determining absolute bioavailability (F) of a compound where the iv preparation is a prodrug, the F of the CAP-base preparation was assumed to equal 100% for the purposes of this study. The apparent F of CAP-S and CAP-P, were therefore determined by dividing their respective AUC by each patient's CAP-base AUC. Body C1 was determined by the formula dose. F/AUC;, whereas the Vdarea was determined by Cl/P. The peak CAP concentration and time to peak were determined directly from the semilogarithmic plot of each patient's serum concentration time curve. In those instances where the rate of CAP absorption appeared slower than the rate of elimination, the CAP absorption rate constant was determined, and this unusual phenomenon was confirmed by the percent absorbed-time plot (14) . Pharmacokinetic parameter estimates dependent on P were then analyzed under the conditions of the "flip-flop" phenomenon (15, 16) . Statistical evaluation was performed with the paired and unpaired Student's t test and analysis of variance.
RESULTS
Ten patients (six male) were enrolled into the study. The biodisposition characteristics of CAP-P and CAP-base in the presence or absence of PER were evaluated in all 10 patients, whereas, the biodisposition characteristics of CAP-S were evaluated in eight patients with and 10 patients without PER, respectively. Nine patients used Pancrease as their routine PER therapy and one patient used Coatazyme-S. Patient characteristics are shown in Table 1 covery was <40% in all patients reflecting marked reduction in exocrine pancreatic function.
The ability of Pancrease to cleave the palmitate ester of CAP-P in vitro is shown in Figure I . Similar degrees of palmitate cleavage were observed at the 2-h sampling for both 2 or 4 capsules. At 4 h, 49% of the palmitate ester was cleaved when incubated with 4 Pancrease capsules, compared to 3 1 % with 2 Pancrease capsules. Lipase activity at 4 h was 98% of that initially present. Figure 2 depicts mean (+-SD) CAP serum concentration time curves observed after administration of the three different preparations without PER. Peak CAP concentrations were highest after CAP-S administration. They occurred at the first sampling time, 15 min after completion of the iv infusion, and averaged 14.9 mg/liter. Similar concentrations were observed after CAPbase administration. These averaged 13.4 mg/liter but occurred 2.3 h after oral drug administration. In contrast, the serum concentration time profile observed after CAP-P administration was markedly different from those observed with either the CAP-S or CAP-base preparations. Serum concentrations were substantially lower throughout the 0.25-to 6-h sampling time for CAP-P. Peak CAP concentrations after CAP-P administra- tion occurred at 2.2 h averaging 3.2 mg/liter. The CAP-P peak concentration was significantly lower than that observed after CAP-S ( p < 0.001) and CAP-base ( p < 0.001). In addition, time to peak after CAP-P administration was also significantly prolonged as compared to CAP-S (p < 0.001) although similar to that observed with CAP-base. In two patients who received CAP-P, drug absorption continued throughout the 12-h sampling period. Their data are not included in Figure 2 (see below) . Twelve-h trough concentrations were similar for all three CAP preparations ranging from 0.8-1.1 mg/liter.
The pharmacokinetic parameters determined with or without PER for the three different CAP formulations are shown in Table  2 . In four patients, two who received CAP-P with PER and two who received CAP-P without PER, CAP continued to be absorbed throughout the 12-h study period. We were unable to perform a pharmacokinetic analysis of CAP-P elimination in these patients, and thus, they are not included in the CAP-P data analysis.
The greatest amount of active CAP in systemic circulation was observed after administration of the CAP-base formulation. In the absence of PER, the CAP AUC after CAP-base was more than the CAP-S AUC and nearly twice as much as the AUC determinations calculated following CAP-P dosing ( p < 0.001).
Although PER did not affect the AUC values for CAP-base, PER significantly increased the AUC after CAP-P administration (p < 0.05) (Fig. 3) . Additionally, the AUC after iv CAP-S was less when infused concomitantly with oral PER than without PER (p < 0.05) ( Table 2 ). These AUC differences define the differences in bioavailability observed with CAP-S and CAP-P while using CAP-base as the reference standard. The bioavailability of active CAP for the CAP-S prodrug formulation average 84% without PER and 69% with PER, whereas the bioavailability of the CAP-P prodrug formulation without PER averaged 42% increasing by almost 50 to 64% with the addition of PER (Table  2) .
Substantial variation was observed in the absorption of CAP from the CAP-P preparation, independent of PER. The bioavailability of CAP from CAP-P with PER ranged from 32 to 99% compared to 19 to 65% without PER. As mentioned previously in two patients who received CAP-P with and two without PER, drug absorption was incomplete at the end of the 12-h sampling period preventing pharmacokinetic analysis. In contrast, the CAP-S formulation demonstrated consistently higher bioavailability ranging from 52-103% with and 54-122% without PER, respectively.
With the exception of AUC, similar pharmacokinetic parameter values were observed for CAP-base and CAP-S formulations ( Table 2 ). The average t~/~ of CAP ranged from 2.6 to 3.2 h, Vdarea from 1 .O to 1.2 liter/kg and total body C14.3 to 4.5 ml/ min/kg. In contrast, the t , and Vdarea determinations for CAP-P were significantly different. The CAP-P tllx was significantly prolonged as compared to either CAP-base ( p < 0.05 with PER; p < 0.02 without PER) or CAP-S ( p < 0.05 with or without PER), with similar differences observed for Vdarea. These differences, for both the t~/~ and Vdarea are most likely a result of prolonged absorption of CAP from the CAP-P formulation. However, because the biodisposition of CAP once liberated from the prodrug formulation and entering the vascular compartment should be identical to that observed with CAP administered in any other formulations an alternative pharmacokinetic approach must be applied to the analysis of CAP-P biodisposition. Thus, we also analyzed our CAP-P concentration-time data under the conditions of a "flip-flop" phenomena (15, 16) . This approach to pharmacokinetic data analysis has been suggested for those situations where a compound's rate of absorption is slower than the elimination rate. These circumstances are suggested by our initial CAP-P results (Table 2) . Using this method of data analysis, the CAP-P t , and Vdarea approached values very similar to those observed after CAP-base and CAP-S administration (Table  3) . Fig. 3 . Effect of concurrent pancreatic enzyme replacement on the biodisposition of CAP-P. Numeric plot of mean (kSD) serum concentration versus time for chloramphenicol after CAP-P (n = 8) (0) with exogenous pancreatic enzyme replacement, and CAP-P (n = 8) (O), and CAP-base (n = 10) (0) without exogenous pancreatic enzyme replacement. Table 2 .
DISCUSSION
Patients with CF frequently receive outpatient antibiotic therapy in an attempt to prolong periods between hospitalization. Although advances in the methods available for ambulatory parenteral drug administration have been realized ( 1 7, 18), oral antibiotics continue to have widespread use. At the present time, there are three CAP formulations available for the treatment of systemic infection; two of these are prodrugs. Both CAP-S for iv administration and CAP-P the oral liquid preparation, lack antimicrobial activity and require hydrolysis in vivo for activation. In contrast, the capsule preparation, CAP-base contains free CAP in its active form. Despite the long-term availability and use of CAP preparations in CF patients, little pharmacologic data regarding CAP pharmacology is available on this compound for these patients (1 9-2 1) .
Although early investigators reported therapeutic CAP serum concentrations after CAP-P administration in CF patients (2 1, 22), Palmer et al. (21) reported low serum concentrations that
:ol preparations in patients with CF (mean (SD)]
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increased with the coadministration of pancreatic extract. Despite these preliminary data, to our knowledge, no complete pharmacokinetic evaluation of CAP has been performed in CF patients. Moreover, the frequent occurrence of exocrine pancreatic insufficiency in CF patients underscores the need to assess the absorption characteristics of the CAP-P preparation, because pancreatic lipases appears important in the liberation of active CAP from this preparation (2) . The pharmacokinetic data generated herein reveal a number of differences in the biodisposition characteristics among the three CAP preparations. The greatest amount of active CAP available in systemic circulation (F), as evidenced by AUC determinations, was observed with the oral CAP-base preparation. Although it is rare that an oral preparation of a drug is more bioavailable than the iv form, this is a direct result of the prodrug nature of the CAP-S iv preparation. Previous studies in non-CF children have reported between 5 and 73% of an administered CAP-S dose recovered in the urine as the inactive succinate ester demonstrating substantial variability in in vivo hydrolysis (22, 23) . This variability in the in vivo hydrolysis of the succinate ester most likely explains the differences observed in F for CAP-S when administered with or without PER. Independent of these differences in drug F between the CAP-base and CAP-S preparations, both formulations consistently achieved and maintained serum concentrations exceeding the MIC of important nonpseudomonal pathogens. In contrast to the similarities observed in the biodisposition profiles with CAP-base and CAP-S, marked differences were observed with the CAP-P preparation. Up to 6 h after administration, CAP serum concentrations were substantially less after CAP-P administration as compared with either CAP-S or CAP-base (Figs. 2 and 3) . Comparison of absorption characteristics between CAP-base and CAP-P when evaluated without PER revealed a significantly lower peak concentration ( p < 0.00 1) for the CAP-P formulation (Table 2 ; Fig.   2 ). This may partially be explained by the fact that patients with CF have decreased amounts of pancreatic lipase, and therefore cannot consistently hydrolyze CAP-P to CAP for absorption. In addition to these differences, pharmacokinetic analysis was not possible in four patients (two with and two without PER) due to continued absorption throughout the 12-h study period.
The absorption characteristics observed in our CF patients after CAP-P administration are markedly different from the "adequate" absorption reported by early investigators (19, 20) and the biodisposition characteristics described in unaffected infants, children, and adults (24) (25) (26) . Serum CAP concentrations after CAP-P administration have often exceeded those after iv CAP-S substantiating the use of CAP-P for the treatment of serious pediatric infections (26, 27) . In contrast, our CAP-P biodisposition data more closely resemble that observed in neonates (28) where incomplete, prolonged, erratic absorption of CAP and poor exocrine pancreatic function (29) has been described. This is consistent with more recent preliminary data in CF patients (2 1).
The CAP-P tH and Vdarea data described herein (Table 2 ) should be interpreted with caution. The comparative pharma-cokinetic data for CAP-base and CAP-S or CAP-P from this study and others (25) (26) (27) strongly suggest that CAP from the CAP-P preparation continues to be absorbed during the majority of the 12-h study period. This fact is supported by the significantly prolonged CAP-P t , and Vdarea which are pharmacokinetic parameters heavily dependent on the terminal elimination rate constant p. Thus, these differences in t~ and Vdarea are most likely artifactual, reflecting the unreliable absorption characteristics of the CAP-P formulation in CF patients. Although is used mathematically to calculate the "tail" of the AUC determination (AUC?), this parameter estimate is much less dependent on p than tl/, or Vdarea. However, as a result of the apparently prolonged (3, it is possible that the CAP-P F estimates shown in Table 2 are overestimated. Assessment of the CAP AUC; and AUC; for the CAP-P ~revaration demonstrates that the AUCi, accounted for, on the Bv&age, 83.9% with and 71.2% without PER, the total AUC;. The decreased influence of , B on the AUC; determination is also reflected by the minimal differences observed between the CAP-P, CAP-base, and CAP-S body C1 (Table 2) . Moreover, the suggestion of prolonged absorption with the CAP-P formulation is further supported by the relatively equivalent CAP-P tl12 and Vdarea parameter estimates obtained when analyzing these data under the conditions of the "flip-flop" phenomena (1 5, 16) ( Table 3 ).
The addition of PER significantly increased the F and peak concentration of CAP-P over CAP-P administration without PER ( Table 2 ). The finding of increased absorption of CAP-P when administered with PER was expected because pancreatic lipase is believed to be responsible for cleaving the palmitate ester (2). Glazko et al. (2) first established that pancreatic-biliary secretions were necessary for CAP-P absorption using the rat model, and that a crude bacterial lipase preparation was capable of completely hydrolyzing small amounts of CAP-P. Although PER increased the AUC and peak CAP concentration of the CAP-P preparation, serum concentrations were far below those achieved with CAP-base or CAP-S and may provide inadequate antibacterial activity systemically. It is possible that a greater amount of CAP would have been systemically available from the CAP-P formulation if a larger number of PER capsules would have been administered. This possibility is supported by our in vitro evaluation of palmitate cleavage which showed greater CAP-P hydrolysis when four capsules were used rather than two capsules (Fig. 1) . However, CAP was administered after an overnight fast to minimize any potential interference in CAP absorption or PER activity by gastric contents. Furthermore, because exogenous pancreatic enzymes are known intestinal mucosal initants (30) , it appeared prudent to administer only 1 PER capsule during the study period. Clinically, 4 Pancrease capsules was the maximum dose used by any of our study patients during a regular meal, and our in vitro study suggests that as many as 4 Pancrease capsules, containing a total of 16,000 units of lipase, would at best hydrolyze only 50% of a small amount of CAP-P in 4 h (Fig. 1) . Other investigators have also demonstrated correlations between poor CAP-P absorption and decreased in vitro hydrolysis using different commercial CAP-P preparations (3 1).
The results of our investigation reveal clinically important pharmacokinetic differences in the biodisposition of CAP in children with CF. Our data support the use of either the CAPbase or CAP-S preparation, when indicated, in the treatment of CF patients. Both formulations showed similar pharmacokinetic parameter estimates and achieved adequate and predictable concentrations in serum which exceeded the MIC of many important nonpseudomonal pathogens. In contrast, markedly different characteristics were observed after administration of the CAP-P formulation. The unpredictable and decreased absorption combined with substantially reduced serum CAP concentrations would recommend against the routine use of the CAP-P formulation in CF patients who require PER. Although PER appeared to improve the overall F of CAP-P, in the presence of the observed variation one would question the reliability of this drug formulation in consistently achieving therapeutic serum and tissue concentrations.
